Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lucentis And Avastin Stack Up In CATT, Forcing Genentech/Novartis To Play Defense

This article was originally published in The Pink Sheet Daily

Executive Summary

The efficacy of low-cost Avastin and pricier Lucentis for the treatment of wet-AMD are similar in the first head-to-head clinical trial to compare the two drugs, though Novartis and Genentech call out safety uncertainties.

Related Content

OIG Raises Reimbursement Policy Questions For Avastin And Lucentis In Wake Of CATT Findings
Avastin-Related Eye Infections Could Bring FDA Pressure On Compounding Pharmacies
Ready To Launch But Nowhere To Go: Regeneron's Eylea Gets FDA Delay
Lucentis Shines In Diabetic Eye Disease, But Competition Looms From Cheap, Off-Label Avastin
Eylea's Dosing Regimen Is Key Question As FDA Takes Draft Labeling To Advisory Committee
NICE Recommends Ozurdex For Macular Edema; Off-Label Comparative Analysis Carries The Day
Allergan Licenses Molecular Partners' Anti-VEGF Protein For Ophthalmologic Indications
Regeneron's VEGF Trap-Eye Caught In CATT's Claws
Deals Of The Week: Johnson & Johnson/Synthes, Kadmon/Nano Terra, Lilly/Medtronic
Regeneron/Bayer Bullish On Wet-AMD Drug But Commercial Success Is No Guarantee





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts